<DOC>
	<DOCNO>NCT02523976</DOCNO>
	<brief_summary>In single-center , open-label , control , prospective clinical trial , total 30 Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph+ALL ) patient enrol . Dasatinib 100 mg per day give orally along combination chemotherapy start day 8 induction chemotherapy . Dasatinib give continuously ( 's tolerable ) 2 year since achievement complete remission ( CR ) part consolidation chemotherapy maintenance therapy.Patients receive allogeneic hematopoietic stem cell transplantation ( HSCT ) autologous HSCT whenever possible first CR . Otherwise , finish consolidation chemotherapy . The purpose current study determine clinical efficacy tolerability combination therapy Dasatinib multi-agent chemotherapy newly-diagnosed Ph+ ALL .</brief_summary>
	<brief_title>Dasatinib Combined With Chemotherapy Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>In single-center , open-label , Phase II study , nonrandomized , control , prospective clinical trial , total 30 Philadelphia chromosome-positive acute lymphoblastic leukemia ( Ph+ALL ) patient enrolled.Patients diagnose accord morphologic , immunologic , cytogenetic molecular ( MICM ) criterion , include bone marrow morphology , immunophenotype , cytogenetic molecular genetic ( BCR/ABL gene , qualitative quantitative analysis ) examination . Dasatinib 100 mg per day give orally along combination chemotherapy start day 8 induction chemotherapy . Dasatinib give continuously ( 's tolerable ) 2 year since achievement complete remission ( CR ) part consolidation chemotherapy maintenance therapy.Patients receive allogeneic hematopoietic stem cell transplantation ( HSCT ) , patient keep BCR/ABL negative receive autologous HSCT whenever possible first CR . Otherwise , finish consolidation chemotherapy . Total duration follow-up 2 year last enrollment . Pre-treatment evaluation include complete blood count ( CBC ) reticulocyte count , chemistry , electrolytes , coagulation , hepatitis profile , chest X-ray.Evaluation treatment include : CBC every two day myelosuppression , chemistry , electrolytes , coagulation cycle chemotherapy . Quantitative PCR ( RQ-PCR ) Bcr-Abl do bone marrow mononuclear cell diagnosis , CR , cycle consolidation chemotherapy , every 3 month maintenance therapy . For patient undergo allogeneic HSCT , quantitative PCR Bcr-Abl do bone marrow mononuclear cell initiation conditioning , every 3 month . PCR do IS standardized lab . Side effect combination therapy monitor described accord Common Toxicity Criteria , version 4.0 ( National Cancer Institute , USA ) . The purpose current study determine clinical efficacy tolerability combination therapy Dasatinib multi-agent chemotherapy newly-diagnosed Ph+ ALL .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>1 . Patients age 18 60 year De novo Philadelphia chromosome positive ( Philadelphia chromosome positive BCR/ABL transcript positive ) acute lymphoblastic leukemia . 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance status 2 . 3 . Adequate end organ function define : Total bilirubin ≤ 1.5 x upper limit normal（ULN） ; serum glutamicoxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) ≤ 2.5 x ULN ; Creatinine ≤ 1.5 x ULN ; Serum amylase lipase ≤ 1.5 x ULN ; Alkaline phosphatase ≤ 2.5 x ULN unless consider tumor relate ; Patients must adequate cardiac function ( ejection fraction ≥ 45 % Multiple Gated Acquisition ( MUGA ) scan ) . 4 . Patients must follow laboratory value ( ≥ low limit normal ( LLN ) correct within normal limit supplement prior first dose study medication . ) : Potassium ≥ LLN ; Magnesium ≥ LLN ; Phosphorus ≥ LLN 5 . Patients sign inform consent form . 1 . Impaired cardiac function : Long QT syndrome know family history long QT syndrome ; clinically significant rest brachycardia ( &lt; 50 beat per minute ) ; ejection fraction &lt; 45 % MUGA scan . QTc interval &gt; 450 msec baseline ECG ( use QTcF formula ) . If QTcF interval &gt; 450 msec electrolyte within normal range , electrolyte correct patient rescreened QTc . Myocardial infarction within 12 month prior start study ; clinically significant heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension , uncontrolled arrhythmia ) . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug . 2 . Other concurrent severe and/or uncontrolled medical condition : Patients another primary malignant disease , except currently require treatment ; acute chronic liver , pancreatic severe renal disease ; another severe and/or lifethreatening medical disease . 3 . Patients : ( ) pregnant , ( b ) breast feeding , ( c ) childbearing potential without negative pregnancy test prior baseline ( ) male female childbearing potential unwilling use contraceptive precaution throughout trial ( postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential ) . 4. Who know human deficiency virus ( HIV ) positive . 5 . Use investigational agent last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoid</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>dasatinib</keyword>
</DOC>